Effect of siponimod on progressive multiple sclerosis
What was tested
Treatment tested
- Siponimod
Sphingosine 1-phosphate receptor Edg-1 agonist
What it measured
Main measures
The study endpoint is the change (assumed to be a reduction) of the susceptibility of the rim lesions after treatment with siponimod in comparison to the “natural” change of this parameter during a recent period-time preceding treatment (no later than two years before) with siponimod, so that for each patient an internal comparison will be available.
MRI lesionsSmouldering inflammation
Other measures (1)
To evaluate the effect of siponimod in reducing the number of SEL comparing to the period prior the treatment (retrospective phase) with the study phase (T3 vs T12 and T3 vs T24).; To describe the individual changes in CSF levels of specific makers of activated microglia/macrophages (sCD14, sCD163, TNF, sTNFR1, sTNFR2, Chitinase 3-1like) and of neuronal/axonal damage (neurofilament-light chains, p
Disability progressionSmouldering inflammationBlood or spinal fluid markersThinking and memoryImmune responseSafety
Loading reviews and guidelines…
Related trials
- GR-2021-12373041
Phase 4 · Recruiting
Still running
- Exploring the effect of a novel therapy on intrathecal inflammation in patients with MS
Phase 4 · Moved to EU CTIS registry
- ITASIA
Completed
No result found
- SIPO20
Phase 4 · Recruiting
Still running
- SWISSMASIA
Stopped early
Stopped early
- Study to Assess the Efficacy of Mayzent on Microglia in S…
Phase 2 / Phase 3 · Stopped early
Stopped early
History
- In scope changed from true to false
Started
Oct 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error